Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Journal of the American College of Cardiology

Volumn 73, Issue 24, 2019, Pages 3210-3227

  Wilson, Peter W F ^a   Polonsky, Tamar S ^a   Miedema, Michael D ^a   Khera, Amit ^a   Kosinski, Andrzej S ^a   Kuvin, Jeffrey T ^a  

^a NONE

Author keywords

ACC AHA Clinical Practice Guidelines; ACC AHA Evidence Review Committee; biomarkers; cardiovascular disease; cholesterol; coronary artery calcium score; diabetes mellitus; drug therapy; ezetimibe; Guidelines; hydroxymethylglutaryl CoA reductase inhibitors statins; hypercholesterolemia; LDL cholesterol; lipids; patient compliance; pharmacological; primary prevention; proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9) inhibitors; risk assessment; risk reduction discussion; risk treatment discussion; secondary prevention

Indexed keywords

ALIROCUMAB; ANACETRAPIB; ATORVASTATIN; BOCOCIZUMAB; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; ENZYME INHIBITOR; EVACETRAPIB; EVOLOCUMAB; EZETIMIBE; LAROPIPRANT; NICOTINIC ACID; SIMVASTATIN; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; CARDIOLOGY; CARDIOVASCULAR DISEASE; CLASSIFICATION; HYPERCHOLESTEROLEMIA; MEDICATION THERAPY MANAGEMENT; PROCEDURES; PSYCHOLOGY; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CARDIOLOGY; CARDIOVASCULAR DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; MEDICATION THERAPY MANAGEMENT; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 85067042721     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.11.004     Document Type: Article

References (35)

1. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 Pt B (2014), 2889–2934.
2. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
3. Ridker, P.M., Revkin, J., Amarenco, P., et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 376 (2017), 1527–1539.
4. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
5. Schwartz, G.G., Steg, P.G., Szarek, M., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379 (2018), 2097–2107.
6. Lincoff, A.M., Nicholls, S.J., Riesmeyer, J.S., et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 376 (2017), 1933–1942.
7. Group HTRC Bowman, L., Hopewell, J.C., et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 377 (2017), 1217–1227.
8. Group HTC Landray, M.J., Haynes, R., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
9. Grundy, S.M., Stone, N.J., Bailey, A.L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73 (2019), e285–e350.
10. Jacobs, A.K., Kushner, F.G., Ettinger, S.M., et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), 213–265.
11. Cholesterol Treatment Trialists’ (CTT) Collaboration Baigent, C., Blackwell, L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
12. Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1500–1509.
13. Ginsberg, H.N., Elam, M.B., Lovato, L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
14. Schwartz, G.G., Olsson, A.G., Abt, M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367 (2012), 2089–2099.
15. AIM-HIGH Investigators Boden, W.E., Probstfield, J.L., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
16. Giugliano, R.P., Cannon, C.P., Blazing, M.A., et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 137 (2018), 1571–1582.
17. Cohen, J.C., Boerwinkle, E., Mosley, T.H. Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006), 1264–1272.
18. Sabatine, M.S., Leiter, L.A., Wiviott, S.D., et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 5 (2017), 941–950.
19. Giugliano, R.P., Mach, F., Zavitz, K., et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med 377 (2017), 633–643.
20. Giugliano, R.P., Pedersen, T.R., Park, J.G., et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390 (2017), 1962–1971.
21. Bonaca, M.P., Nault, P., Giugliano, R.P., et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 137 (2018), 338–350.
22. Barter, P.J., Caulfield, M., Eriksson, M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2109–2122.
23. Tardif, J.C., Rheaume, E., Lemieux Perreault, L.P., et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 8 (2015), 372–382.
24. Tardif, J.C., Rhainds, D., Brodeur, M., et al. Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes. Circ Cardiovasc Genet 9 (2016), 340–348.
25. Nissen, S.E., Pillai, S.G., Nicholls, S.J., et al. ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease: a nested case-control study. JAMA Cardiol 3 (2018), 401–408.
26. Canner, P.L., Berge, K.G., Wenger, N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986), 1245–1255.
27. Taylor, A.J., Sullenberger, L.E., Lee, H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004), 3512–3517.
28. Brown, B.G., Zhao, X.Q., Chait, A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001), 1583–1592.
29. Boden, W.E., Probstfield, J.L., Anderson, T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
30. Serban, M.C., Colantonio, L.D., Manthripragada, A.D., et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol 69 (2017), 1386–1395.
31. Cannon, C.P., Braunwald, E., McCabe, C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
32. LaRosa, J.C., Grundy, S.M., Waters, D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005), 1425–1435.
33. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
34. Robinson, J.G., Huijgen, R., Ray, K., et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol 68 (2016), 2412–2421.
35. Ridker, P.M., Everett, B.M., Thuren, T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.